Opendata, web and dolomites

CardioProtectMI SIGNED

A New Drug Therapy for the treatment of ST Elevated Myocardial Infarction

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 CardioProtectMI project word cloud

Explore the words cloud of the CardioProtectMI project. It provides you a very rough idea of what is the project "CardioProtectMI" about.

deaths    plan    million    readiness    14    later    efficacy    business    therapies    protective    itself    first    improvement    market    causing    validation    inflammatory    mi    resother    infarction    death    medium    humans    reported    clinical    human    anti    provider    treatments    smei    pharma    incidence    engage    decreases    prepare    injury    consequence    innovation    restoration    drug    acute    survival    tissue    blood       strategies    generation    stages    peptide    tissues    drugs    date    ensuing    safety    supporting    utmost    therapeutics    therapy    52    cell    serious    positioning    reveal    heart    class    congestive    company    opportunity    failed    stakeholders    mitigate    rate    aps    mortality    ihd    animal    biotechnology    stopping    emerged    therapeutic    damage    reperfusion    prove    inflammation    severe    strategic    trials    recommend    cardio    disease    procedure    ischaemic    alone    resolution    400    12    effect    guidelines    candidate    myocardial    models    flow    10    chronic   

Project "CardioProtectMI" data sheet

The following table provides information about the project.

Coordinator
RESOTHER PHARMA APS 

Organization address
address: DRONNINGGARDS ALLE 136
city: KOBENHAVN
postcode: 2840
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    RESOTHER PHARMA APS DK (KOBENHAVN) coordinator 50˙000.00

Map

 Project objective

Ischaemic heart disease (IHD) is the leading cause of mortality in Europe with about 1.8 million reported deaths per year in Europe alone. A serious consequence of IHD can be stopping blood flow to the heart causing a Myocardial Infarction (MI). In the most severe cases this has a mortality rate between 6% and 14%. Clinical guidelines recommend immediate restoration of the blood flow via reperfusion therapy. However, this procedure results in high acute mortality (10%) and a significant incidence of congestive heart failure (12%) due to inflammation and ensuing cell death of the myocardial tissues. Current treatments do not provide a cardio-protective effect to mitigate this. Several potential therapies have emerged as promising cardio-protective therapeutic strategies for severe cases of MI, but up to date these have all failed to prove efficacy in later stages of human clinical trials. ResoTher Pharma ApS is a biotechnology company focused on developing a new class of therapeutics targeting the resolution of inflammatory responses. The company´s first drug candidate is a novel peptide with unique cardio-protective capabilities. Results from animal models reveal promising tissue-protective effects - decreases in myocardial damage related to the reperfusion injury (52%) and an overall improvement of the survival rate after an MI (up to 400%). The clinical validation of the lead drug will be key to demonstrate safety and efficacy in humans and allow ResoTher to establish itself in the chronic inflammatory disease market. The present SMEi Phase 1 will be of utmost importance to engage key stakeholders and prepare the clinical development plan in readiness for implementation during the Innovation Project. The clinical validation of the lead drug will lead to a significant business opportunity for ResoTher, supporting the company´s medium term strategic positioning as a unique provider of a new generation of anti-inflammatory drugs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CARDIOPROTECTMI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CARDIOPROTECTMI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

CoLumbo (2019)

AUTOMATED DIAGNOSTICS AND RADIOLOGICAL READING FROM LUMBAR SPINE MRI

Read More  

ClosedToe (2020)

Sock toe closing system for circular knitting machines

Read More  

Tolka Pro (2019)

Manual Assistant (hand for upper limb disability) – a new approach designed to restore user's manual capabilities.

Read More